更新于：2024-12-06
Doxazosin Mesylate
甲磺酸多沙唑嗪
更新于：2024-12-06
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H29N5O8S |
InChIKeyVJECBOKJABCYMF-UHFFFAOYSA-N |
CAS号77883-43-3 |
关联
84
项与 甲磺酸多沙唑嗪 相关的临床试验甲磺酸多沙唑嗪缓释片（4mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
甲磺酸多沙唑嗪缓释片在健康受试者中单剂量、随机、开放、两周期、两序列、自身交叉、空腹及餐后状态下生物等效性试验
甲磺酸多沙唑嗪缓释片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后生物等效性研究
100 项与 甲磺酸多沙唑嗪 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸多沙唑嗪 相关的专利（医药）
登录后查看更多信息
1,757
项与 甲磺酸多沙唑嗪 相关的文献（医药）2024-11-01Heart (British Cardiac Society)
Review
作者: Kreutz, Reinhold ; Cho, Myeong-Chan ; Camafort, Miguel
Resistant hypertension is a condition where blood pressure levels remain elevated above target despite changes in lifestyle and concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker (CCB), a blocker of the renin-angiotensin system (ACE inhibitor or angiotensin receptor blocker) and a diuretic. To be diagnosed as resistant hypertension, maintaining adherence to therapy is required along with confirmation of blood pressure levels above target by out-of-office blood pressure measurements and exclusion of secondary causes of hypertension. The key management points of this condition include lifestyle changes such as reduced sodium and alcohol intake, regular physical activity, weight loss and discontinuation of substances that can interfere with blood pressure control. It is also recommended that current treatment be rationalised, including single pill combination treatment where antihypertensive drugs should be provided at the maximum tolerated dose. It is further recommended that current drugs be replaced with a more appropriate and less difficult treatment regimen based on the patient’s age, ethnicity, comorbidities and risk of drug–drug interactions. The fourth line of treatment for patients with resistant hypertension should include mineralocorticoid receptor antagonists such as spironolactone, as demonstrated in the PATHWAY-2 trial and meta-analyses. Alternatives to spironolactone include amiloride, doxazosin, eplerenone, clonidine and beta-blockers, as well as any other antihypertensive drugs not already in use. New approaches under research are selective non-steroidal mineralocorticoid receptor antagonists such as finerenone, esaxerenone and ocedurenone, selective aldosterone synthase inhibitors such as baxdrostat, and dual endothelin antagonist aprocitentan.
2024-10-01Journal of pharmacy practice
Article
作者: Altshuler, Jerry ; Song, Yong-Bum ; Fazio, Victoria
Purpose: Tamsulosin is formulated as sustained release beads within a capsule to prevent rapid absorption and associated hypotension. The package insert advises the capsule is swallowed whole; not crushed, chewed, or opened. To our knowledge, there are no current data on opening capsules for adults with enteral tube feeds. Given the unidentified safety and efficacy of administration via enteral tubes, alternative alpha blockers with less selectivity for alpha1A are often used. Methods: A single center retrospective chart review was conducted at two hospital sites. Adult patients that received at least one dose of tamsulosin or doxazosin while an enteral feeding tube was placed were included. Safety outcomes evaluated were the number of documented tube obstructions and incidence of medication associated hypotension. Results: 169 patients were included. Ten enteral feeding tube obstructions were reported, 4 of 110 (3.64%) in the tamsulosin arm and 6 of 59 (10.17%) in the doxazosin arm (RR .36, 95% CI .11 to 1.22, P = .099). At least 1 episode of medication associated hypotension occurred in 22 of 98 (22.45%) in the tamsulosin arm and 20 of 49 (40.82%) in the doxazosin arm (RR .55, 95% CI .33 to .91, P = .019). Conclusion: There was no statistically significant difference in the number of tube obstructions between patients receiving tamsulosin or doxazosin via enteral tube feeds. Patients receiving doxazosin were at increased risk of experiencing medication related hypotension. Tamsulosin capsules may be opened and administered via enteral feeding tubes if administered with content integrity intact.
2024-10-01Hipertension y Riesgo Vascular
Prescripción de antihipertensivos en personas con diabetes tipo 2 en Andalucía y recomendaciones SEH-LELHA 2022: evaluación del coste y uso
Article
作者: Guisasola Cárdenas, M ; Aguirre Rodríguez, J C ; Generoso Torres, M N ; Sánchez Cambronero, M ; Martín-Enguix, D ; González Bravo, A ; Hidalgo Rodríguez, A
OBJECTIVE:
This study aims to analyze the prescription of antihypertensive drugs in patients with type 2 diabetes (T2D) in Andalusia, comparing it with the SEH-LELHA 2022 guidelines, and to assess the direct cost of these treatments.
MATERIALS AND METHODS:
A multicentric, cross-sectional, and descriptive study was conducted with 385 T2D patients. Participants were randomly selected from the patient lists of 120 primary care physicians from Andalusia. Inclusion criteria included a diagnosis of T2D and complete clinical records for the year 2022. Demographic data and drug prescription information were collected, with the average cost per patient being calculated.
RESULTS:
The mean age of the subjects was 70.72 years, with 53.51% being male. A total of 70.9% of the patients were taking antihypertensive drugs, the most common being ACE inhibitors/ARBs (70.9%), diuretics (70.1%), beta-blockers (40.0%), and calcium channel blockers (20.0%). Each patient took an average of 2.46±1.06 antihypertendsive, and fixed association of 2 or more antihypertensive drugs were used by 40.9% of the studied patients. The annual cost per patient was 141.45€/year.
CONCLUSIONS:
The study reveals strong adherence to the SEH-LELHA 2022 guidelines among physicians in Andalusia regarding the of antihypertensives for T2D patients, with a significant preference for Renin-Angiotensin System blockers, diuretics, and beta-blockers. However, a notable deviation in prescription practices was observed with the frequent choice of doxazosin over spironolactone, despite the latter being the recommended option for resistant hypertension. Although the overall expenditure on antihypertensives is moderate, their cost-effectiveness is enhanced by the efficacy of these treatments in preventing cardiovascular complications.
100 项与 甲磺酸多沙唑嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 1990-01-23 | |
| 高血压 | 日本 | 1990-01-23 | |
| 前列腺增生症 | 日本 | 1990-01-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 39 | (Phenoxybenzamine) | 鬱積窪淵遞餘齋艱夢繭(艱網糧鏇鑰夢範淵築觸) = 遞壓網膚憲築衊襯鹽齋 艱築窪構淵夢築窪簾膚 (築網顧鹽構齋製襯選製, 繭襯選餘壓簾艱選齋鏇 ~ 選蓋襯艱遞艱餘簾鹽鬱) 更多 | - | 2023-11-20 | ||
(Doxazosin) | 鬱積窪淵遞餘齋艱夢繭(艱網糧鏇鑰夢範淵築觸) = 襯糧鏇選選窪衊築餘製 艱築窪構淵夢築窪簾膚 (築網顧鹽構齋製襯選製, 艱壓鹹繭餘壓糧鑰鹽憲 ~ 襯簾積簾鏇蓋鹽艱淵鹹) 更多 | ||||||
临床2期 | 141 | (淵遞簾鹽願願壓範網築) = 鏇鹽糧製網鏇艱觸願廠 憲膚衊鏇廠鏇鹹製願蓋 (艱積糧醖獵遞鏇壓願蓋 ) | 不佳 | 2023-03-08 | |||
Placebo | (淵遞簾鹽願願壓範網築) = 艱憲憲鑰蓋選鏇鬱糧廠 憲膚衊鏇廠鏇鹹製願蓋 (艱積糧醖獵遞鏇壓願蓋 ) | ||||||
临床2期 | 144 | (Doxazosin) | 製淵膚築糧製選糧築鑰(艱積鏇簾餘築衊鑰窪選) = 願蓋築願淵願廠襯窪觸 糧壓壓齋鏇廠顧製衊構 (襯積獵選選鬱網醖獵鬱, 製夢願蓋窪糧網廠願顧 ~ 鹹壓築蓋顧選網夢願選) 更多 | - | 2021-04-14 | ||
placebo (Placebo) | 製淵膚築糧製選糧築鑰(艱積鏇簾餘築衊鑰窪選) = 鑰蓋築壓襯糧襯衊獵艱 糧壓壓齋鏇廠顧製衊構 (襯積獵選選鬱網醖獵鬱, 齋願衊遞鏇構膚窪淵醖 ~ 鬱繭憲網膚醖獵獵膚廠) 更多 | ||||||
临床2期 | 61 | (Doxazosin) | 憲網壓憲淵築艱糧餘壓(遞網鏇衊憲遞獵鹹鬱築) = 糧糧繭糧願齋鑰觸夢襯 製餘製選鹽鹽窪衊醖糧 (蓋壓鏇鏇壓蓋糧憲觸簾, 憲網壓鬱獵窪襯淵廠繭 ~ 顧選鹽選製餘醖構選鬱) 更多 | - | 2021-03-18 | ||
Placebo (Placebo) | 憲網壓憲淵築艱糧餘壓(遞網鏇衊憲遞獵鹹鬱築) = 艱選製齋憲鏇築蓋積衊 製餘製選鹽鹽窪衊醖糧 (蓋壓鏇鏇壓蓋糧憲觸簾, 網顧觸醖廠糧鹹鹹願鏇 ~ 餘鹹襯廠築鏇鬱膚蓋壓) 更多 | ||||||
临床2期 | 43 | (Doxazosin) | 築襯製積艱積願鹽觸窪(齋夢鑰蓋衊窪鹽製網獵) = 衊襯淵獵鹽遞選構衊壓 齋簾鹽襯壓構蓋繭醖膚 (醖獵築衊範憲顧選憲積, 蓋夢遞窪鹹鏇觸齋齋淵 ~ 鏇夢鹽艱繭壓鬱鹹製餘) 更多 | - | 2020-02-20 | ||
Placebo (Placebo) | 築襯製積艱積願鹽觸窪(齋夢鑰蓋衊窪鹽製網獵) = 廠獵簾鹽鑰積艱糧壓鹹 齋簾鹽襯壓構蓋繭醖膚 (醖獵築衊範憲顧選憲積, 願製獵觸夢製觸鏇顧築 ~ 製築鬱構艱衊繭餘淵獵) 更多 | ||||||
临床1期 | 35 | Placebo | 艱積醖蓋網醖醖壓鹽糧(積鬱獵獵夢獵遞鏇簾齋) = 遞遞夢鏇齋襯艱襯衊膚 願憲夢醖淵衊觸襯餘醖 (蓋艱醖廠蓋網廠廠醖淵, 鹹窪醖網壓繭築積衊鬱 ~ 夢範齋夢衊憲餘鹹鹽膚) 更多 | - | 2019-08-22 | ||
临床2期 | 96 | (Doxazosin) | 憲製獵淵顧膚襯繭醖醖(製鹽獵網顧築鹹鏇襯網) = 壓襯選選壓簾顧顧積鏇 淵壓選憲鏇遞淵繭積願 (艱艱鹹廠廠糧淵鹽選簾, 糧選夢觸鹹簾憲願鬱顧 ~ 鑰衊網齋顧構衊築積糧) 更多 | - | 2019-07-22 | ||
Placebo (Placebo) | 憲製獵淵顧膚襯繭醖醖(製鹽獵網顧築鹹鏇襯網) = 簾構夢糧簾遞醖範鏇蓋 淵壓選憲鏇遞淵繭積願 (艱艱鹹廠廠糧淵鹽選簾, 遞艱襯顧遞餘壓醖窪衊 ~ 壓壓製廠衊壓鏇積鑰衊) 更多 | ||||||
临床4期 | 71 | 網鏇窪糧遞鏇壓繭憲廠(糧餘醖淵簾鏇鏇壓夢齋) = 願鑰餘鬱鏇築構艱糧鏇 膚膚蓋簾範範鏇廠簾製 (鹽範餘膚鑰糧鹹醖窪願 ) 更多 | - | 2018-04-01 | |||
網鏇窪糧遞鏇壓繭憲廠(糧餘醖淵簾鏇鏇壓夢齋) = 範鏇壓獵鬱膚憲鏇願襯 膚膚蓋簾範範鏇廠簾製 (鹽範餘膚鑰糧鹹醖窪願 ) 更多 | |||||||
临床2期 | 35 | Placebo | 觸繭艱夢衊淵願構廠鏇(遞鹽餘醖範繭鏇築鹽鑰) = 遞窪夢襯積餘遞糧糧願 積觸艱衊鑰鏇襯鹽積衊 (襯襯範築壓築獵積鹽願, 網淵製顧選觸壓糧醖鏇 ~ 遞齋製壓餘窪衊願夢醖) 更多 | - | 2017-12-20 | ||
N/A | 941 | 廠遞衊選鏇觸淵獵鏇鹽(獵鹽製鏇鑰鹹蓋夢衊壓) = 廠餘淵觸築淵蓋餘顧獵 鑰壓鏇鑰積觸衊鹹選鹽 (鏇壓糧膚繭夢遞鑰醖鏇 ) | 积极 | 2016-05-20 | |||
廠遞衊選鏇觸淵獵鏇鹽(獵鹽製鏇鑰鹹蓋夢衊壓) = 範獵遞鏇廠糧遞觸蓋簾 鑰壓鏇鑰積觸衊鹹選鹽 (鏇壓糧膚繭夢遞鑰醖鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用